Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-25-006734
Filing Date
2025-02-14
Accepted
2025-02-14 14:03:31
Documents
46
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 520383
2 ex10-16.htm EX-10.16 20955
3 ex10-17.htm EX-10.17 18463
4 ex31-1.htm EX-31.1 18721
5 ex31-2.htm EX-31.2 18558
6 ex32-1.htm EX-32.1 6922
7 ex32-2.htm EX-32.2 6977
  Complete submission text file 0001493152-25-006734.txt   2936548

Data Files

Seq Description Document Type Size
8 XBRL SCHEMA FILE nxen-20241231.xsd EX-101.SCH 21919
9 XBRL CALCULATION FILE nxen-20241231_cal.xml EX-101.CAL 26070
10 XBRL DEFINITION FILE nxen-20241231_def.xml EX-101.DEF 102463
11 XBRL LABEL FILE nxen-20241231_lab.xml EX-101.LAB 210060
12 XBRL PRESENTATION FILE nxen-20241231_pre.xml EX-101.PRE 162905
49 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 322568
Mailing Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246
Business Address 4340 E KENTUCKY AVE SUITE 206 GLENDALE CO 80246 3034957583
NEXIEN BIOPHARMA, INC. (Filer) CIK: 0001625288 (see all company filings)

EIN.: 262049376 | State of Incorp.: DE | Fiscal Year End: 0630
Type: 10-Q | Act: 34 | File No.: 000-55320 | Film No.: 25626516
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)